ENVB vs. GRI, PLRZ, BPTH, SNOA, GNPX, PPBT, SNPX, CPHI, ALBT, and LIPO
Should you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include GRI Bio (GRI), Polyrizon (PLRZ), Bio-Path (BPTH), Sonoma Pharmaceuticals (SNOA), Genprex (GNPX), Purple Biotech (PPBT), Synaptogenix (SNPX), China Pharma (CPHI), Avalon GloboCare (ALBT), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical products" industry.
Enveric Biosciences vs.
Enveric Biosciences (NASDAQ:ENVB) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Enveric Biosciences' return on equity of -221.54% beat GRI Bio's return on equity.
GRI Bio has a consensus price target of $11.50, suggesting a potential upside of 2,671.08%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Enveric Biosciences.
Enveric Biosciences has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -2.15, meaning that its share price is 315% less volatile than the S&P 500.
In the previous week, GRI Bio had 5 more articles in the media than Enveric Biosciences. MarketBeat recorded 6 mentions for GRI Bio and 1 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 0.26 beat GRI Bio's score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the media.
13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 3.2% of Enveric Biosciences shares are owned by insiders. Comparatively, 0.1% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Enveric Biosciences received 2 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote.
Summary
GRI Bio beats Enveric Biosciences on 7 of the 13 factors compared between the two stocks.
Get Enveric Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enveric Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ENVB) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ENVB Stock Alerts